Regents Of The University Of California Exits Position in Dermira Inc (DERM)

Dermira Inc (DERM) : Regents Of The University Of California has sold out all of its stake in Dermira Inc during the most recent quarter, according to the disclosure filed by the company on Aug 15, 2016 with the SEC. The investment management company has sold out 12,208 shares of Dermira Inc which is valued at $384,430.

Other Hedge Funds, Including , Rock Springs Capital Management Lp boosted its stake in DERM in the latest quarter, The investment management firm added 64,900 additional shares and now holds a total of 354,900 shares of Dermira Inc which is valued at $11,175,801. Dermira Inc makes up approx 0.78% of Rock Springs Capital Management Lp’s portfolio.Aisling Capital reduced its stake in DERM by selling 868,230 shares or 89.43% in the most recent quarter. The Hedge Fund company now holds 102,593 shares of DERM which is valued at $3,230,654. Dermira Inc makes up approx 0.69% of Aisling Capital’s portfolio.Allianz Asset Management Ag reduced its stake in DERM by selling 1,201 shares or 1.0% in the most recent quarter. The Hedge Fund company now holds 118,365 shares of DERM which is valued at $3,727,314. Dermira Inc makes up approx 0.01% of Allianz Asset Management Ag’s portfolio. Raymond James Associates added DERM to its portfolio by purchasing 54,685 company shares during the most recent quarter which is valued at $1,722,031. Dermira Inc makes up approx 0.01% of Raymond James Associates’s portfolio. Cable Hill Partners added DERM to its portfolio by purchasing 261 company shares during the most recent quarter which is valued at $8,420. Dermira Inc makes up approx 0.01% of Cable Hill Partners’s portfolio.

Dermira Inc opened for trading at $30.94 and hit $32.26 on the upside on Thursday, eventually ending the session at $32.22, with a gain of 3.80% or 1.18 points. The heightened volatility saw the trading volume jump to 1,97,402 shares. Company has a market cap of $1,140 M.

Many Wall Street Analysts have commented on Dermira Inc. Company shares were Reiterated by Wedbush on Jun 2, 2016 to “Outperform”, Firm has raised the Price Target to $ 46 from a previous price target of $42 .Company shares were Reiterated by Needham on Jun 2, 2016 to “Buy”, Firm has raised the Price Target to $ 46 from a previous price target of $42 .

Dermira Inc. is a specialty biopharmaceutical company focused on bringing medical dermatology products to dermatologists and their patients. The Company’s portfolio of five product candidates includes three late-stage product candidates. The late-stage product candidates are Cimzia (certolizumab pegol) which the Company is developing in collaboration with UCB Pharma S.A. (UCB) DRM04 and DRM01. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor or TNF inhibitor that is approved and marketed by UCB for the treatment of numerous inflammatory diseases spanning multiple medical specialties. DRM04 is a topical small-molecule anticholinergic product the Company is developing for the treatment of hyperhidrosis or excessive sweating. DRM01 is a topical small-molecule sebum inhibitor the Company is developing for the treatment of acne.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Dermira Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Dermira Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.